A bioavailable cathepsin S nitrile inhibitor abrogates tumor development

Molecular Cancer

Volumn 15, Issue 1, 2016, Pages

  Wilkinson, Richard D A ^a   Young, Andrew ^a   Burden, Roberta E ^a   Williams, Rich ^a   Scott, Christopher J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Cancer; Cathepsin; Inhibitor; Therapeutic; Tool

Indexed keywords

CATHEPSIN S; CATHEPSIN S INHIBITOR; KI 67 ANTIGEN; CATHEPSIN; NITRILE; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL INVASION; CELL MIGRATION ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG SCREENING; ENZYME KINETICS; ENZYME SUBSTRATE; EXPERIMENTAL NEOPLASM; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; TUMOR INVASION; TUMOR XENOGRAFT; TUNEL ASSAY; TURNOVER TIME; VALIDATION STUDY; ANGIOGENESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOAVAILABILITY; C57BL MOUSE; CARCINOGENESIS; CHEMISTRY; DRUG EFFECTS; GENETICS; INTRACELLULAR SPACE; MCF-7 CELL LINE; METABOLISM; PATHOLOGY; PROTEIN DEGRADATION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; BIOLOGICAL AVAILABILITY; CARCINOGENESIS; CATHEPSINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTRACELLULAR SPACE; MCF-7 CELLS; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PHYSIOLOGIC; NITRILES; PROTEASE INHIBITORS; PROTEOLYSIS; RECOMBINANT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84963805097     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/s12943-016-0513-7     Document Type: Article

References (50)

1. Brix K, Scott CJ, Heck, MMS. Compartmentalisation of proteolysis. In: Brix, K, Stocker W, editors. Proteases: Structure and Funtion. Vienna: Springer; 2013. p. 85-126.
2. Puente XS, Sánchez LM, Gutiérrez-Fernández A, Velasco G, López-Otín C. A genomic view of the complexity of mammalian proteolytic systems. Biochem Soc Trans. 2005;33:331-4.
3. Rawlings ND, Barrett AJ, Bateman A. MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res. 2012;40:D343-50.
4. Turk B, Turk D, Turk V. Protease signalling: the cutting edge. EMBO J. 2012;31:1630-43.
5. Repnik U, Starr AE, Overall CM, Turk B. Cysteine Cathepsins Activate ELR Chemokines and Inactivate Non-ELR Chemokines. J Biol Chem. 2015;290:13800-13811.
6. Wilkinson RDA, Magorrian SM, Williams R, Young A, Small DM, Scott CJ, Burden RE. CCL2 is transcriptionally controlled by the lysosomal protease cathepsin S in a CD74-dependent manner. Oncotarget. 2015;6:29725-39.
7. Fonović M, Turk B. Cysteine cathepsins and their potential in clinical therapy and biomarker discovery. Proteomics Clin Appl. 2014;8:416-26.
8. Abbenante G, Fairlie DP. Protease inhibitors in the clinic. Med Chem. 2005;1:71-104.
9. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov. 2006;5:785-99.
10. Chang WSW, Wu HR, Yeh CT, Wu CW, Chang JY. Lysosomal Cysteine Proteinase Cathepsin S as a Potential Target for Anti-Cancer Therapy. J Cancer Mol. 2007;3:5-14.
11. Small DM, Burden RE, Scott CJ. The Emerging Relevance of the Cysteine Protease Cathepsin S in Disease. Clin Rev Bone Miner Metab. 2011;9:122-32.
12. Wilkinson RDA, Williams R, Scott CJ, Burden RE. Cathepsin S: therapeutic, diagnostic, and prognostic potential. Biol Chem. 2015;396:867-82.
13. Flannery T, McQuaid S, McGoohan C, McConnell RS, McGregor G, Mirakhur M, et al. Cathepsin S expression: An independent prognostic factor in glioblastoma tumors-A pilot study. Int J Cancer. 2006;119:854-60.
14. Gormley JA, Hegarty SM, O'Grady A, Stevenson MR, Burden RE, Barrett HL, et al. The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study. Br J Cancer. 2011;105:1487-94.
15. Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 2006;20:543-56.
16. Small DM, Burden RE, Jaworski J, Hegarty SM, Spence S, Burrows JF, et al. Cathepsin S from both tumor and tumor-associated cells promote cancer growth and neovascularization. Int J Cancer. 2013;133:2102-12.
17. Wang B, Sun J, Kitamoto S, Yang M, Grubb A, Chapman HA, et al. Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem. 2006;281:6020-9.
18. Veillard F, Saidi A, Burden RE, Scott CJ, Gillet L, Lecaille F, et al. Cysteine cathepsins S and L modulate anti-angiogenic activities of human endostatin. J Biol Chem. 2011;286:37158-67.
19. Sevenich L, Bowman RL, Mason SD, Quail DF, Rapaport F, Elie BT, et al. Analysis of tumor- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nat Cell Biol. 2014;16:876-88.
20. Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL, et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev. 2010;24:241-55.
21. Verdoes M, Edgington LE, Scheeren FA, Leyva M, Blum G, Weiskopf K, et al. A nonpeptidic cathepsin S activity-based probe for noninvasive optical imaging of tumor-associated macrophages. Chem Biol. 2012;19:619-28.
22. Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 2011;25:2465-79.
23. Burden RE, Snoddy P, Buick RJ, Johnston JA, Walker B, Scott CJ. Recombinant cathepsin S propeptide attenuates cell invasion by inhibition of cathepsin L-like proteases in tumor microenvironment. Mol Cancer Ther. 2008;7:538-47.
24. Burden RE, Gormley JA, Jaquin TJ, Small DM, Quinn DJ, Hegarty SM, et al. Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis. Clin Cancer Res. 2009;15:6042-51.
25. Li CS, Deschenes D, Desmarais S, Falgueyret JP, Gauthier JY, Kimmel DB, et al. Identification of a potent and selective non-basic cathepsin K inhibitor. Bioorg Med Chem Lett. 2006;16:1985-9.
26. Gauthier JY, Black WC, Courchesne I, Cromlish W, Desmarais S, Houle R, et al. The identification of potent selective, and bioavailable cathepsin S inhibitors. Bioorg Med Chem Lett. 2007;17:4929-33.
27. Samokhin AO, Lythgo PA, Gauthier JY, Percival MD, Brömme D. Pharmacological inhibition of cathepsin S decreases atherosclerotic lesions in Apoe-/- mice. J Cardiovasc Pharmacol. 2010;56:98-105.
28. Samokhin AO, Gauthier JY, Percival MD, Brömme D. Lack of cathepsin activities alter or prevent the development of lung granulomas in a mouse model of sarcoidosis. Respir Res. 2011;12:13.
29. Jaworski J, de la Vega M, Fletcher SJ, McFarlane C, Greene MK, Smyth AW, et al. USP17 is required for clathrin mediated endocytosis of epidermal growth factor receptor. Oncotarget. 2014;5:6964-75.
30. Schönefuss A, Wendt W, Schattling B, Schulten R, Hoffmann K, Stuecker M, et al. Upregulation of cathepsin S in psoriatic keratinocytes. Exp Dermatol. 2010;19:e80-8.
31. Nakagawa T, Roth W, Wong P, Nelson A, Farr A, Deussing J, Villadangos JA, et al. Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. Science. 1998;280:450-3.
32. Schmid D, Jarvis GE, Fay F, Small DM, Greene MK, Majkut J, et al. Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity. Cell Death Dis. 2014;5:e1454.
33. Morrison JF, Walsh CT. The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol. 1988;61:201-301.
34. Riese RJ, Wolf PR, Brömme D, Natkin LR, Villadangos JA, Ploegh HL, et al. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity. 1996;4:357-66.
35. Shi GP, Villadangos JA, Dranoff G, Small C, Gu L, Haley KJ, et al. Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity. 1999;10:197-206.
36. Ward C, Kuehn D, Burden RE, Gormley JA, Jaquin TJ, Gazdoiu M, et al. Antibody Targeting of Cathepsin S Inhibits Angiogenesis and Synergistically Enhances Anti-VEGF. PLoS One. 2010;5:e12543.
37. Seo HR, Bae S, Lee YS. Radiation-induced cathepsin S is involved in radioresistance. Int J Cancer. 2009;124:1794-801.
38. Huang T, Chen Z, Fang L. Curcumin inhibits LPS-induced EMT through downregulation of NF-ΚB-Snail signalling in breast cancer cells. Oncol Rep. 2013;29:117-24.
39. Zhang X, Zhang Y, Li Y. β-elemene decreases cell invasion by upregulating E-cadherin expression in MCF-7 human breast cancer cells. Oncol Rep. 2013;30:747-50.
40. Shao N, Zhao X, Zhang X, Luo M, Zuo X, Huang S, et al. Notch1 signaling regulates the epithelial-mesenchymal transition and invasion of breast cancer in a Slug-dependent manner. Mol Cancer. 2015;14:28.
41. Li Y, Huang R, Wang L, Hao J, Zhang Q, Ling R, et al. microRNA-762 promotes breast cancer cell proliferation and invasion by targeting IRF7 expression. Ceell Prolif. 2015;48:643-9.
42. Fernández PL, Farré X, Nadal A, Fernández E, Peiró N, Sloane BF, et al. Expression of cathepsins B and S in the progression of prostate carcinoma. Int J Cancer. 2001;95:51-5.
43. Lindahl C, Simonsson M, Bergh A, Thysell E, Antti H, Sund M, et al. Increased levels of macrophage-secreted cathepsin S during prostate cancer progression in TRAMP mice and patients. Cancer Genomics Proteomics. 2009;6:149-59.
44. Xu J, Li D, Ke Z, Liu R, Maubach G, Zhuo L. Cathepsin S is aberrantly overexpressed in human hepatocellular carcinoma. Mol Med Rep. 2009;2:713-8.
45. Deschamps K, Cromlish W, Weicker S, Lamontagne S, Huszar SL, Gauthier JY, et al. Genetic and pharmacological evaluation of cathepsin s in a mouse model of asthma. Am J Respir Cell Mol Biol. 2011;45:81-7.
46. Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat Rev Cancer. 2007;7:645-58.
47. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9:239-52.
48. Ryschich E, Lizdenis P, Ittrich C, Benner A, Stahl S, Hamann A, et al. Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma. Cancer Res. 2006;66:198-211.
49. Shi GP, Sukhova GK, Kuzuya M, Ye Q, Du J, Zhang Y, et al. Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ Res. 2003;92:493-500.
50. Burden RE, Gormley JA, Kuehn D, Ward C, Kwok HF, Gazdoiu M, et al. Inhibition of Cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas. Biochimie. 2012;94:487-93.